PT2193133E - Imidazolotiadiazóis para utilização como inibidores de proteína quinases - Google Patents

Info

Publication number

PT2193133E

PT2193133E PT88064373T PT08806437T PT2193133E PT 2193133 E PT2193133 E PT 2193133E PT 88064373 T PT88064373 T PT 88064373T PT 08806437 T PT08806437 T PT 08806437T PT 2193133 E PT2193133 E PT 2193133E

Authority

PT

Portugal

Prior art keywords

imidazo

formula

compound

thiadiazol

phenyl

Prior art date

2007-09-27

Links

• Espacenet
• Global Dossier
• Discuss

• BOXRDDIXJOUZLV-UHFFFAOYSA-N 2h-imidazo[4,5-d]thiadiazole Chemical class N1SC2=NC=NC2=N1 BOXRDDIXJOUZLV-UHFFFAOYSA-N 0.000 title description 10
• 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title description 3
• 239000003909 protein kinase inhibitor Substances 0.000 title description 3
• 150000001875 compounds Chemical class 0.000 claims description 308
• -1 4-fluoro-1-naphthyl Chemical group 0.000 claims description 197
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 114
• 125000001424 substituent group Chemical group 0.000 claims description 64
• 238000006243 chemical reaction Methods 0.000 claims description 59
• 125000005843 halogen group Chemical group 0.000 claims description 56
• 229910052739 hydrogen Inorganic materials 0.000 claims description 54
• 238000000034 method Methods 0.000 claims description 50
• 239000001257 hydrogen Substances 0.000 claims description 49
• 125000000217 alkyl group Chemical group 0.000 claims description 44
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 41
• 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 38
• 125000003118 aryl group Chemical group 0.000 claims description 37
• 206010028980 Neoplasm Diseases 0.000 claims description 36
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 36
• 125000001072 heteroaryl group Chemical group 0.000 claims description 31
• 201000011510 cancer Diseases 0.000 claims description 30
• 150000003839 salts Chemical class 0.000 claims description 30
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 27
• 125000002947 alkylene group Chemical group 0.000 claims description 25
• 230000008569 process Effects 0.000 claims description 25
• 150000002431 hydrogen Chemical group 0.000 claims description 23
• 238000002360 preparation method Methods 0.000 claims description 23
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 22
• 201000010099 disease Diseases 0.000 claims description 22
• 238000011282 treatment Methods 0.000 claims description 22
• 239000012453 solvate Substances 0.000 claims description 20
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 19
• 150000001408 amides Chemical class 0.000 claims description 19
• 239000003814 drug Substances 0.000 claims description 19
• 125000004122 cyclic group Chemical group 0.000 claims description 18
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 16
• 239000002671 adjuvant Substances 0.000 claims description 15
• 239000003085 diluting agent Substances 0.000 claims description 15
• 239000008194 pharmaceutical composition Substances 0.000 claims description 15
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 13
• 229910052731 fluorine Inorganic materials 0.000 claims description 12
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 12
• 229940124597 therapeutic agent Drugs 0.000 claims description 12
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 11
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
• 239000011737 fluorine Substances 0.000 claims description 11
• 230000009467 reduction Effects 0.000 claims description 11
• 238000006722 reduction reaction Methods 0.000 claims description 11
• 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 10
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 9
• 230000002062 proliferating effect Effects 0.000 claims description 9
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 8
• 229910052757 nitrogen Inorganic materials 0.000 claims description 8
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 7
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 7
• 230000004663 cell proliferation Effects 0.000 claims description 6
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
• 125000005647 linker group Chemical group 0.000 claims description 6
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 6
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
• QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 claims description 5
• 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims description 5
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 5
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
• 150000003512 tertiary amines Chemical class 0.000 claims description 5
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 4
• 201000001320 Atherosclerosis Diseases 0.000 claims description 4
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 4
• 206010018364 Glomerulonephritis Diseases 0.000 claims description 4
• 208000009905 Neurofibromatoses Diseases 0.000 claims description 4
• 208000031481 Pathologic Constriction Diseases 0.000 claims description 4
• 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 4
• 201000004681 Psoriasis Diseases 0.000 claims description 4
• 206010003246 arthritis Diseases 0.000 claims description 4
• 239000013066 combination product Substances 0.000 claims description 4
• 229940127555 combination product Drugs 0.000 claims description 4
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
• 201000004931 neurofibromatosis Diseases 0.000 claims description 4
• 208000015768 polyposis Diseases 0.000 claims description 4
• 208000005069 pulmonary fibrosis Diseases 0.000 claims description 4
• 238000006268 reductive amination reaction Methods 0.000 claims description 4
• 208000037803 restenosis Diseases 0.000 claims description 4
• 150000003335 secondary amines Chemical class 0.000 claims description 4
• 230000036262 stenosis Effects 0.000 claims description 4
• 208000037804 stenosis Diseases 0.000 claims description 4
• 230000002792 vascular Effects 0.000 claims description 4
• UOFCXVBAUZFSQT-UHFFFAOYSA-N 2-(cyclopropylmethylamino)-n-phenylimidazo[2,1-b][1,3,4]thiadiazole-5-sulfonamide Chemical compound C=1N=C2SC(NCC3CC3)=NN2C=1S(=O)(=O)NC1=CC=CC=C1 UOFCXVBAUZFSQT-UHFFFAOYSA-N 0.000 claims description 3
• YKGMCRDGQBHBRZ-UHFFFAOYSA-N 3-[2-(4-fluorophenoxy)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-n,n-dimethylaniline Chemical compound CN(C)C1=CC=CC(C=2N3N=C(OC=4C=CC(F)=CC=4)SC3=NC=2)=C1 YKGMCRDGQBHBRZ-UHFFFAOYSA-N 0.000 claims description 3
• BCAKJJZKSLTUOK-UHFFFAOYSA-N 4-[2-(4-fluoroanilino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C2N1N=C(NC=1C=CC(F)=CC=1)S2 BCAKJJZKSLTUOK-UHFFFAOYSA-N 0.000 claims description 3
• WCMVGMVOYZYSQE-UHFFFAOYSA-N 4-[2-[(4-fluorophenyl)methylamino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C2N1N=C(NCC=1C=CC(F)=CC=1)S2 WCMVGMVOYZYSQE-UHFFFAOYSA-N 0.000 claims description 3
• 206010062016 Immunosuppression Diseases 0.000 claims description 3
• 241000534944 Thia Species 0.000 claims description 3
• 229910052799 carbon Inorganic materials 0.000 claims description 3
• 230000001506 immunosuppresive effect Effects 0.000 claims description 3
• 208000027866 inflammatory disease Diseases 0.000 claims description 3
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 3
• CVFQBICVTJEPDF-UHFFFAOYSA-N n-ethyl-2-(ethylamino)imidazo[2,1-b][1,3,4]thiadiazole-5-sulfonamide Chemical compound CCNS(=O)(=O)C1=CN=C2SC(NCC)=NN21 CVFQBICVTJEPDF-UHFFFAOYSA-N 0.000 claims description 3
• 230000003071 parasitic effect Effects 0.000 claims description 3
• 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
• 230000003612 virological effect Effects 0.000 claims description 3
• ISRPTTSIDVGQRW-UHFFFAOYSA-N 1-[3-[6-chloro-2-(2-methylpropylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]ethanone Chemical compound ClC=1N=C2SC(NCC(C)C)=NN2C=1C1=CC=CC(C(C)=O)=C1 ISRPTTSIDVGQRW-UHFFFAOYSA-N 0.000 claims description 2
• HEWKCLUEWLJWBV-UHFFFAOYSA-N 2-[(4-fluorophenyl)methylamino]-n-phenylimidazo[2,1-b][1,3,4]thiadiazole-5-sulfonamide Chemical compound C1=CC(F)=CC=C1CNC(S1)=NN2C1=NC=C2S(=O)(=O)NC1=CC=CC=C1 HEWKCLUEWLJWBV-UHFFFAOYSA-N 0.000 claims description 2
• PDSYHMDJYQFIGQ-UHFFFAOYSA-N 2-phenyl-5-pyridin-3-ylimidazo[2,1-b][1,3,4]thiadiazole Chemical compound C=1N=C2SC(C=3C=CC=CC=3)=NN2C=1C1=CC=CN=C1 PDSYHMDJYQFIGQ-UHFFFAOYSA-N 0.000 claims description 2
• INWQOVNJGBKZIT-UHFFFAOYSA-N 5-(4-fluorophenyl)-2-phenylimidazo[2,1-b][1,3,4]thiadiazole Chemical compound C1=CC(F)=CC=C1C1=CN=C2N1N=C(C=1C=CC=CC=1)S2 INWQOVNJGBKZIT-UHFFFAOYSA-N 0.000 claims description 2
• GGRZTZVOZQAFCY-UHFFFAOYSA-N 6-chloro-5-(3,4-dimethoxyphenyl)-n-(2-methoxyethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound ClC=1N=C2SC(NCCOC)=NN2C=1C1=CC=C(OC)C(OC)=C1 GGRZTZVOZQAFCY-UHFFFAOYSA-N 0.000 claims description 2
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
• 238000004519 manufacturing process Methods 0.000 claims description 2
• JAMJUPRNDQABOV-UHFFFAOYSA-N n-[4-[2-(4-fluoroanilino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=CN=C2N1N=C(NC=1C=CC(F)=CC=1)S2 JAMJUPRNDQABOV-UHFFFAOYSA-N 0.000 claims description 2
• WWKUJMBUCXUERB-UHFFFAOYSA-N n-benzyl-2-(dimethylamino)-n-methylimidazo[2,1-b][1,3,4]thiadiazole-5-carboxamide Chemical compound C=1N=C2SC(N(C)C)=NN2C=1C(=O)N(C)CC1=CC=CC=C1 WWKUJMBUCXUERB-UHFFFAOYSA-N 0.000 claims description 2
• BDFZYAAZZOPRMG-UHFFFAOYSA-N n-ethyl-2-[(4-fluorophenyl)methylamino]imidazo[2,1-b][1,3,4]thiadiazole-5-sulfonamide Chemical compound N=1N2C(S(=O)(=O)NCC)=CN=C2SC=1NCC1=CC=C(F)C=C1 BDFZYAAZZOPRMG-UHFFFAOYSA-N 0.000 claims description 2
• 239000008177 pharmaceutical agent Substances 0.000 claims description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
• PJGLCBCBNJMVCD-UHFFFAOYSA-N 1-[3-[2-(cyclopropylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC(C=2N3N=C(NCC4CC4)SC3=NC=2)=C1 PJGLCBCBNJMVCD-UHFFFAOYSA-N 0.000 claims 1
• QORVTJMUYZLSGU-UHFFFAOYSA-N 1-[3-[[2-(2-methoxyethylamino)-7,7a-dihydroimidazo[2,1-b][1,3,4]thiadiazol-5-yl]methylamino]phenyl]ethanone Chemical compound S1C(NCCOC)=NN2C1NC=C2CNC1=CC=CC(C(C)=O)=C1 QORVTJMUYZLSGU-UHFFFAOYSA-N 0.000 claims 1
• WRTXUFKSQJFCCH-UHFFFAOYSA-N 1-[3-[[2-(2-methylpropylamino)-7,7a-dihydroimidazo[2,1-b][1,3,4]thiadiazol-5-yl]methylamino]phenyl]ethanone Chemical compound S1C(NCC(C)C)=NN2C1NC=C2CNC1=CC=CC(C(C)=O)=C1 WRTXUFKSQJFCCH-UHFFFAOYSA-N 0.000 claims 1
• UXJOPIADSJBWJO-UHFFFAOYSA-N 6-chloro-n-[(4-fluorophenyl)methyl]-5-(4-methoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(OC)=CC=C1C1=C(Cl)N=C2N1N=C(NCC=1C=CC(F)=CC=1)S2 UXJOPIADSJBWJO-UHFFFAOYSA-N 0.000 claims 1
• ONCCWDRMOZMNSM-FBCQKBJTSA-N compound Z Chemical compound N1=C2C(=O)NC(N)=NC2=NC=C1C(=O)[C@H]1OP(O)(=O)OC[C@H]1O ONCCWDRMOZMNSM-FBCQKBJTSA-N 0.000 claims 1
• SFOYFWHJOQHZRH-UHFFFAOYSA-N n-[4-[2-(4-fluorophenoxy)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=CN=C2N1N=C(OC=1C=CC(F)=CC=1)S2 SFOYFWHJOQHZRH-UHFFFAOYSA-N 0.000 claims 1
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 192
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 83
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 76
• 239000000203 mixture Substances 0.000 description 69
• 238000005481 NMR spectroscopy Methods 0.000 description 61
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 57
• 101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 description 46
• 239000000543 intermediate Substances 0.000 description 43
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 39
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 38
• 239000000377 silicon dioxide Substances 0.000 description 36
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
• 239000007787 solid Substances 0.000 description 31
• 239000002904 solvent Substances 0.000 description 30
• 238000000746 purification Methods 0.000 description 29
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
• 238000004440 column chromatography Methods 0.000 description 27
• 102000001253 Protein Kinase Human genes 0.000 description 26
• 108060006633 protein kinase Proteins 0.000 description 26
• 239000011541 reaction mixture Substances 0.000 description 25
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
• 150000001412 amines Chemical class 0.000 description 21
• 230000000694 effects Effects 0.000 description 21
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
• 239000000047 product Substances 0.000 description 19
• 101100297651 Mus musculus Pim2 gene Proteins 0.000 description 18
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 16
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
• 230000015572 biosynthetic process Effects 0.000 description 16
• 210000004027 cell Anatomy 0.000 description 16
• 150000002148 esters Chemical class 0.000 description 16
• 101100297652 Coturnix japonica PIM3 gene Proteins 0.000 description 14
• 108091000080 Phosphotransferase Proteins 0.000 description 14
• 102000020233 phosphotransferase Human genes 0.000 description 14
• 238000003786 synthesis reaction Methods 0.000 description 14
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 13
• 239000000460 chlorine Substances 0.000 description 13
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
• 101100439046 Caenorhabditis elegans cdk-2 gene Proteins 0.000 description 12
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
• 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 12
• 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 12
• 108060006706 SRC Proteins 0.000 description 12
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
• 238000003556 assay Methods 0.000 description 12
• 238000001816 cooling Methods 0.000 description 12
• 239000000243 solution Substances 0.000 description 12
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
• 102000042867 PIM family Human genes 0.000 description 11
• 108091082273 PIM family Proteins 0.000 description 11
• 125000004429 atom Chemical group 0.000 description 11
• 125000005842 heteroatom Chemical group 0.000 description 11
• LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 10
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
• 229910052801 chlorine Inorganic materials 0.000 description 10
• 125000000753 cycloalkyl group Chemical group 0.000 description 10
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
• 239000000651 prodrug Substances 0.000 description 10
• 229940002612 prodrug Drugs 0.000 description 10
• 229910052938 sodium sulfate Inorganic materials 0.000 description 10
• 235000011152 sodium sulphate Nutrition 0.000 description 10
• 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 10
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 9
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
• 239000002585 base Substances 0.000 description 9
• 125000002619 bicyclic group Chemical group 0.000 description 9
• 125000004093 cyano group Chemical group *C#N 0.000 description 9
• 238000001914 filtration Methods 0.000 description 9
• 125000002950 monocyclic group Chemical group 0.000 description 9
• 239000012044 organic layer Substances 0.000 description 9
• 238000012360 testing method Methods 0.000 description 9
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
• 238000003818 flash chromatography Methods 0.000 description 8
• 238000009472 formulation Methods 0.000 description 8
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
• 125000006239 protecting group Chemical group 0.000 description 8
• 235000017557 sodium bicarbonate Nutrition 0.000 description 8
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
• 238000004587 chromatography analysis Methods 0.000 description 7
• 239000012043 crude product Substances 0.000 description 7
• 239000003112 inhibitor Substances 0.000 description 7
• 230000005764 inhibitory process Effects 0.000 description 7
• 238000010898 silica gel chromatography Methods 0.000 description 7
• 239000000126 substance Substances 0.000 description 7
• 125000001544 thienyl group Chemical group 0.000 description 7
• JFHCFWOCRFEOAG-UHFFFAOYSA-N 2-bromoimidazo[2,1-b][1,3,4]thiadiazole Chemical compound C1=CN=C2SC(Br)=NN21 JFHCFWOCRFEOAG-UHFFFAOYSA-N 0.000 description 6
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
• 239000002253 acid Substances 0.000 description 6
• 229910052786 argon Inorganic materials 0.000 description 6
• 210000004369 blood Anatomy 0.000 description 6
• 239000008280 blood Substances 0.000 description 6
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 6
• 229910000024 caesium carbonate Inorganic materials 0.000 description 6
• 239000003054 catalyst Substances 0.000 description 6
• 239000003153 chemical reaction reagent Substances 0.000 description 6
• UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
• 230000000977 initiatory effect Effects 0.000 description 6
• NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 6
• 125000004076 pyridyl group Chemical group 0.000 description 6
• BIYUHJDISSCHKV-UHFFFAOYSA-N 2-(4-fluorophenoxy)-5-iodoimidazo[2,1-b][1,3,4]thiadiazole Chemical compound C1=CC(F)=CC=C1OC(S1)=NN2C1=NC=C2I BIYUHJDISSCHKV-UHFFFAOYSA-N 0.000 description 5
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
• 108700020796 Oncogene Proteins 0.000 description 5
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
• 229910052794 bromium Inorganic materials 0.000 description 5
• 208000035475 disorder Diseases 0.000 description 5
• 125000000524 functional group Chemical group 0.000 description 5
• 125000002541 furyl group Chemical group 0.000 description 5
• 125000001041 indolyl group Chemical group 0.000 description 5
• 229910052744 lithium Inorganic materials 0.000 description 5
• 239000000463 material Substances 0.000 description 5
• 125000002757 morpholinyl group Chemical group 0.000 description 5
• 125000001624 naphthyl group Chemical group 0.000 description 5
• 230000035755 proliferation Effects 0.000 description 5
• 125000003226 pyrazolyl group Chemical group 0.000 description 5
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
• 238000010992 reflux Methods 0.000 description 5
• 239000000725 suspension Substances 0.000 description 5
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 5
• 229910052725 zinc Inorganic materials 0.000 description 5
• 239000011701 zinc Substances 0.000 description 5
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 4
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
• QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
• XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
• 206010025323 Lymphomas Diseases 0.000 description 4
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
• JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
• 210000001744 T-lymphocyte Anatomy 0.000 description 4
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
• 229960000583 acetic acid Drugs 0.000 description 4
• 238000010256 biochemical assay Methods 0.000 description 4
• YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 4
• 239000003638 chemical reducing agent Substances 0.000 description 4
• 238000005859 coupling reaction Methods 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 235000019253 formic acid Nutrition 0.000 description 4
• 230000014509 gene expression Effects 0.000 description 4
• 239000011777 magnesium Substances 0.000 description 4
• 229910052749 magnesium Inorganic materials 0.000 description 4
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
• 229910052760 oxygen Inorganic materials 0.000 description 4
• XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
• 108090000765 processed proteins & peptides Proteins 0.000 description 4
• 108090000623 proteins and genes Proteins 0.000 description 4
• 102000004169 proteins and genes Human genes 0.000 description 4
• 229910052708 sodium Inorganic materials 0.000 description 4
• 239000011734 sodium Substances 0.000 description 4
• 239000000758 substrate Substances 0.000 description 4
• 229910052717 sulfur Inorganic materials 0.000 description 4
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
• 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 description 3
• RMHWWNHEPKGLEW-UHFFFAOYSA-N 1-[3-[2-(oxan-4-ylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC(C=2N3N=C(NCC4CCOCC4)SC3=NC=2)=C1 RMHWWNHEPKGLEW-UHFFFAOYSA-N 0.000 description 3
• LCNFEUXOURGYIS-UHFFFAOYSA-N 1-[3-[2-(thiophen-2-ylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC(C=2N3N=C(NCC=4SC=CC=4)SC3=NC=2)=C1 LCNFEUXOURGYIS-UHFFFAOYSA-N 0.000 description 3
• HHBVKSDIEPYPPS-UHFFFAOYSA-N 2-bromoimidazo[2,1-b][1,3,4]thiadiazole-5-sulfonic acid Chemical compound S1C(Br)=NN2C(S(=O)(=O)O)=CN=C21 HHBVKSDIEPYPPS-UHFFFAOYSA-N 0.000 description 3
• QSKPIOLLBIHNAC-UHFFFAOYSA-N 2-chloro-acetaldehyde Chemical compound ClCC=O QSKPIOLLBIHNAC-UHFFFAOYSA-N 0.000 description 3
• 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 3
• 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 3
• 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 3
• KCEKCKYZZHREFI-UHFFFAOYSA-N 3h-thiadiazol-2-amine Chemical compound NN1NC=CS1 KCEKCKYZZHREFI-UHFFFAOYSA-N 0.000 description 3
• CDMSUMPDCNIYMR-UHFFFAOYSA-N 4-[2-(cyclohexylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C2N1N=C(NC1CCCCC1)S2 CDMSUMPDCNIYMR-UHFFFAOYSA-N 0.000 description 3
• MGRONUXQOUJYNK-UHFFFAOYSA-N 4-[2-(cyclopropylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC(C=2N3N=C(NCC4CC4)SC3=NC=2)=C1 MGRONUXQOUJYNK-UHFFFAOYSA-N 0.000 description 3
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 3
• 125000004487 4-tetrahydropyranyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
• KCEAUFQNCXVWCA-UHFFFAOYSA-N 5-(3-chlorophenyl)-n-(2-methoxyethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1N=C2SC(NCCOC)=NN2C=1C1=CC=CC(Cl)=C1 KCEAUFQNCXVWCA-UHFFFAOYSA-N 0.000 description 3
• NGSIFTAYSMYXTJ-UHFFFAOYSA-N 5-(3-chlorophenyl)-n-(oxan-4-ylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound ClC1=CC=CC(C=2N3N=C(NCC4CCOCC4)SC3=NC=2)=C1 NGSIFTAYSMYXTJ-UHFFFAOYSA-N 0.000 description 3
• OPABNPDQMVRCEB-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(2-methoxyethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1N=C2SC(NCCOC)=NN2C=1C1=CC=C(Cl)C=C1 OPABNPDQMVRCEB-UHFFFAOYSA-N 0.000 description 3
• ZGLYOLGEKPEIMV-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(oxan-4-ylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(Cl)=CC=C1C1=CN=C2N1N=C(NCC1CCOCC1)S2 ZGLYOLGEKPEIMV-UHFFFAOYSA-N 0.000 description 3
• GLYQQFBHCFPEEU-UHFFFAOYSA-N 5-bromo-1,3,4-thiadiazol-2-amine Chemical compound NC1=NN=C(Br)S1 GLYQQFBHCFPEEU-UHFFFAOYSA-N 0.000 description 3
• KSCWJLBBCJEHIQ-UHFFFAOYSA-N 5-iodo-n-(2-methylpropyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound IC1=CN=C2SC(NCC(C)C)=NN21 KSCWJLBBCJEHIQ-UHFFFAOYSA-N 0.000 description 3
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
• 125000000172 C5-C10 aryl group Chemical group 0.000 description 3
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
• 108700020978 Proto-Oncogene Proteins 0.000 description 3
• 102000052575 Proto-Oncogene Human genes 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• 102000004495 STAT3 Transcription Factor Human genes 0.000 description 3
• 108010017324 STAT3 Transcription Factor Proteins 0.000 description 3
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
• 239000004480 active ingredient Substances 0.000 description 3
• 239000000908 ammonium hydroxide Substances 0.000 description 3
• 239000012298 atmosphere Substances 0.000 description 3
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
• 229910052796 boron Inorganic materials 0.000 description 3
• 239000012267 brine Substances 0.000 description 3
• 125000004432 carbon atom Chemical group C* 0.000 description 3
• 150000001735 carboxylic acids Chemical class 0.000 description 3
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
• 238000001035 drying Methods 0.000 description 3
• 125000004185 ester group Chemical group 0.000 description 3
• 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 3
• 238000001704 evaporation Methods 0.000 description 3
• 230000008020 evaporation Effects 0.000 description 3
• 125000000623 heterocyclic group Chemical group 0.000 description 3
• 125000002632 imidazolidinyl group Chemical group 0.000 description 3
• 238000001727 in vivo Methods 0.000 description 3
• 125000002346 iodo group Chemical group I* 0.000 description 3
• 229910052751 metal Inorganic materials 0.000 description 3
• 239000002184 metal Substances 0.000 description 3
• FMMBFVSBNJEBPN-UHFFFAOYSA-N n-(2-methylpropyl)-5-[3-(trifluoromethoxy)phenyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1N=C2SC(NCC(C)C)=NN2C=1C1=CC=CC(OC(F)(F)F)=C1 FMMBFVSBNJEBPN-UHFFFAOYSA-N 0.000 description 3
• QOMHROAYJBUBPV-UHFFFAOYSA-N n-(4-fluorophenyl)-5-iodoimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(F)=CC=C1NC(S1)=NN2C1=NC=C2I QOMHROAYJBUBPV-UHFFFAOYSA-N 0.000 description 3
• BTYWULCWEDPYQF-UHFFFAOYSA-N n-[3-[2-(thiophen-2-ylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2N3N=C(NCC=4SC=CC=4)SC3=NC=2)=C1 BTYWULCWEDPYQF-UHFFFAOYSA-N 0.000 description 3
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
• 239000003921 oil Substances 0.000 description 3
• 230000002018 overexpression Effects 0.000 description 3
• 239000001301 oxygen Substances 0.000 description 3
• 238000007911 parenteral administration Methods 0.000 description 3
• 125000003386 piperidinyl group Chemical group 0.000 description 3
• 210000002307 prostate Anatomy 0.000 description 3
• 125000000168 pyrrolyl group Chemical group 0.000 description 3
• 230000004044 response Effects 0.000 description 3
• 229920006395 saturated elastomer Polymers 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
• 238000010561 standard procedure Methods 0.000 description 3
• 125000003107 substituted aryl group Chemical group 0.000 description 3
• 239000011593 sulfur Substances 0.000 description 3
• 230000004083 survival effect Effects 0.000 description 3
• 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 description 3
• 125000001166 thiolanyl group Chemical group 0.000 description 3
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 3
• VYEWTHXZHHATTA-UHFFFAOYSA-N (4-acetamidophenyl)boronic acid Chemical compound CC(=O)NC1=CC=C(B(O)O)C=C1 VYEWTHXZHHATTA-UHFFFAOYSA-N 0.000 description 2
• COIQUVGFTILYGA-UHFFFAOYSA-N (4-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=C(O)C=C1 COIQUVGFTILYGA-UHFFFAOYSA-N 0.000 description 2
• 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 2
• 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 description 2
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
• 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 2
• LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 2
• 238000005160 1H NMR spectroscopy Methods 0.000 description 2
• IRBKTCFRZKQHMD-UHFFFAOYSA-N 2-(4-fluorophenoxy)imidazo[2,1-b][1,3,4]thiadiazole Chemical compound C1=CC(F)=CC=C1OC(S1)=NN2C1=NC=C2 IRBKTCFRZKQHMD-UHFFFAOYSA-N 0.000 description 2
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
• WMLFBYOCNPFETO-UHFFFAOYSA-N 2-bromo-3h-imidazo[2,1-b][1,3,4]thiadiazole-2-sulfonamide Chemical compound C1=CN=C2SC(S(=O)(=O)N)(Br)NN21 WMLFBYOCNPFETO-UHFFFAOYSA-N 0.000 description 2
• LCAQQRBVDSLLBW-UHFFFAOYSA-N 2-bromoimidazo[2,1-b][1,3,4]thiadiazole-5-sulfonyl chloride Chemical compound S1C(Br)=NN2C(S(=O)(=O)Cl)=CN=C21 LCAQQRBVDSLLBW-UHFFFAOYSA-N 0.000 description 2
• KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 2
• 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 2
• 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 2
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
• DXOLBUFYHXFWOJ-UHFFFAOYSA-N 5-(3-chloro-4-fluorophenyl)-n-(2-methylpropyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1N=C2SC(NCC(C)C)=NN2C=1C1=CC=C(F)C(Cl)=C1 DXOLBUFYHXFWOJ-UHFFFAOYSA-N 0.000 description 2
• VFADMXXTEOMORM-UHFFFAOYSA-N 5-(6-methoxypyridin-3-yl)-n-(2-methylpropyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=NC(OC)=CC=C1C1=CN=C2N1N=C(NCC(C)C)S2 VFADMXXTEOMORM-UHFFFAOYSA-N 0.000 description 2
• ATBXLDQFSPCJLD-UHFFFAOYSA-N 5-[3-(dimethylamino)phenyl]-n-(oxan-4-ylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound CN(C)C1=CC=CC(C=2N3N=C(NCC4CCOCC4)SC3=NC=2)=C1 ATBXLDQFSPCJLD-UHFFFAOYSA-N 0.000 description 2
• CYCKYOCVGGSLSC-UHFFFAOYSA-N 5-iodo-2-phenylimidazo[2,1-b][1,3,4]thiadiazole Chemical compound N=1N2C(I)=CN=C2SC=1C1=CC=CC=C1 CYCKYOCVGGSLSC-UHFFFAOYSA-N 0.000 description 2
• OQFGAXWLSQXCBP-UHFFFAOYSA-N 6-chloro-5-iodo-n-(2-methylpropyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound IC1=C(Cl)N=C2SC(NCC(C)C)=NN21 OQFGAXWLSQXCBP-UHFFFAOYSA-N 0.000 description 2
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 125000000041 C6-C10 aryl group Chemical group 0.000 description 2
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
• 239000007818 Grignard reagent Substances 0.000 description 2
• 239000007995 HEPES buffer Substances 0.000 description 2
• 108010034791 Heterochromatin Proteins 0.000 description 2
• 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 description 2
• 108090000144 Human Proteins Proteins 0.000 description 2
• 102000003839 Human Proteins Human genes 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• 102000000646 Interleukin-3 Human genes 0.000 description 2
• 108010002386 Interleukin-3 Proteins 0.000 description 2
• 108010063738 Interleukins Proteins 0.000 description 2
• 102000015696 Interleukins Human genes 0.000 description 2
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 241000713869 Moloney murine leukemia virus Species 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
• MKIALVWVCSUSRO-UHFFFAOYSA-N N-(cyclopropylmethyl)-5-[3-(trifluoromethyl)phenyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound FC(F)(F)c1cccc(c1)-c1cnc2sc(NCC3CC3)nn12 MKIALVWVCSUSRO-UHFFFAOYSA-N 0.000 description 2
• LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
• PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• 229920001213 Polysorbate 20 Polymers 0.000 description 2
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• 206010042971 T-cell lymphoma Diseases 0.000 description 2
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
• 241000700605 Viruses Species 0.000 description 2
• 241001660687 Xantho Species 0.000 description 2
• YZQQHZXHCXAJAV-UHFFFAOYSA-N [3-(dimethylamino)phenyl]boronic acid Chemical compound CN(C)C1=CC=CC(B(O)O)=C1 YZQQHZXHCXAJAV-UHFFFAOYSA-N 0.000 description 2
• 230000006978 adaptation Effects 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 230000000996 additive effect Effects 0.000 description 2
• 150000001340 alkali metals Chemical group 0.000 description 2
• 125000000304 alkynyl group Chemical group 0.000 description 2
• 229910021529 ammonia Inorganic materials 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 239000012131 assay buffer Substances 0.000 description 2
• 238000003149 assay kit Methods 0.000 description 2
• 210000003719 b-lymphocyte Anatomy 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
• 239000006227 byproduct Substances 0.000 description 2
• 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 2
• 125000002837 carbocyclic group Chemical group 0.000 description 2
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
• PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
• 125000005518 carboxamido group Chemical group 0.000 description 2
• 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
• 230000003197 catalytic effect Effects 0.000 description 2
• 230000022131 cell cycle Effects 0.000 description 2
• 125000001309 chloro group Chemical group Cl* 0.000 description 2
• 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• 239000010949 copper Substances 0.000 description 2
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
• IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 description 2
• 230000010250 cytokine signaling pathway Effects 0.000 description 2
• 238000010511 deprotection reaction Methods 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 229940043279 diisopropylamine Drugs 0.000 description 2
• HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 2
• 230000005284 excitation Effects 0.000 description 2
• 238000000605 extraction Methods 0.000 description 2
• 125000001153 fluoro group Chemical group F* 0.000 description 2
• 239000000417 fungicide Substances 0.000 description 2
• 239000012362 glacial acetic acid Substances 0.000 description 2
• 150000004795 grignard reagents Chemical class 0.000 description 2
• 229910052736 halogen Inorganic materials 0.000 description 2
• 150000002367 halogens Chemical group 0.000 description 2
• 201000005787 hematologic cancer Diseases 0.000 description 2
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
• 125000004404 heteroalkyl group Chemical group 0.000 description 2
• 210000004458 heterochromatin Anatomy 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
• JETOYKBMVCNBTF-UHFFFAOYSA-N imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CN=C2SC(N)=NN21 JETOYKBMVCNBTF-UHFFFAOYSA-N 0.000 description 2
• UVNXNSUKKOLFBM-UHFFFAOYSA-N imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=CSC2=NC=CN21 UVNXNSUKKOLFBM-UHFFFAOYSA-N 0.000 description 2
• 125000002883 imidazolyl group Chemical group 0.000 description 2
• 230000036039 immunity Effects 0.000 description 2
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
• 229940047122 interleukins Drugs 0.000 description 2
• 229910052740 iodine Inorganic materials 0.000 description 2
• 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 2
• 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 2
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
• 125000000842 isoxazolyl group Chemical group 0.000 description 2
• 238000000021 kinase assay Methods 0.000 description 2
• 208000032839 leukemia Diseases 0.000 description 2
• KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
• ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
• 230000003211 malignant effect Effects 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
• 239000012452 mother liquor Substances 0.000 description 2
• 230000035772 mutation Effects 0.000 description 2
• PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
• UCQMPXFLXARWBI-UHFFFAOYSA-N n-(2-methylpropyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CN=C2SC(NCC(C)C)=NN21 UCQMPXFLXARWBI-UHFFFAOYSA-N 0.000 description 2
• KBEMEQFTEFCAAM-UHFFFAOYSA-N n-(2-pyridin-2-ylethyl)-5-[3-(trifluoromethyl)phenyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound FC(F)(F)C1=CC=CC(C=2N3N=C(NCCC=4N=CC=CC=4)SC3=NC=2)=C1 KBEMEQFTEFCAAM-UHFFFAOYSA-N 0.000 description 2
• WREPUICJGAAQOR-UHFFFAOYSA-N n-(4-fluorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(F)=CC=C1NC(S1)=NN2C1=NC=C2 WREPUICJGAAQOR-UHFFFAOYSA-N 0.000 description 2
• FQIMHLFOFUNWEL-UHFFFAOYSA-N n-(4-methoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(OC)=CC=C1NC(S1)=NN2C1=NC=C2 FQIMHLFOFUNWEL-UHFFFAOYSA-N 0.000 description 2
• SYOQEIOUWRVTOT-UHFFFAOYSA-N n-[(2-bromoimidazo[2,1-b][1,3,4]thiadiazol-5-yl)methyl]-3-chloro-4-fluoroaniline Chemical compound C1=C(Cl)C(F)=CC=C1NCC1=CN=C2N1N=C(Br)S2 SYOQEIOUWRVTOT-UHFFFAOYSA-N 0.000 description 2
• XRMZQRNAQVLNSE-UHFFFAOYSA-N n-[3-[2-(2-pyridin-2-ylethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2N3N=C(NCCC=4N=CC=CC=4)SC3=NC=2)=C1 XRMZQRNAQVLNSE-UHFFFAOYSA-N 0.000 description 2
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 230000004770 neurodegeneration Effects 0.000 description 2
• 125000002524 organometallic group Chemical group 0.000 description 2
• 125000002971 oxazolyl group Chemical group 0.000 description 2
• 230000003647 oxidation Effects 0.000 description 2
• 238000007254 oxidation reaction Methods 0.000 description 2
• 229910052763 palladium Inorganic materials 0.000 description 2
• 244000045947 parasite Species 0.000 description 2
• 230000008506 pathogenesis Effects 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
• 230000026731 phosphorylation Effects 0.000 description 2
• 238000006366 phosphorylation reaction Methods 0.000 description 2
• 239000003880 polar aprotic solvent Substances 0.000 description 2
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
• 239000013641 positive control Substances 0.000 description 2
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 125000003373 pyrazinyl group Chemical group 0.000 description 2
• 125000002098 pyridazinyl group Chemical group 0.000 description 2
• 125000000714 pyrimidinyl group Chemical group 0.000 description 2
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
• HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 2
• 230000011664 signaling Effects 0.000 description 2
• 239000000741 silica gel Substances 0.000 description 2
• 229910002027 silica gel Inorganic materials 0.000 description 2
• 239000010703 silicon Substances 0.000 description 2
• 229910052710 silicon Inorganic materials 0.000 description 2
• 229910000104 sodium hydride Inorganic materials 0.000 description 2
• HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 2
• 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 2
• 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
• 125000003831 tetrazolyl group Chemical group 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 2
• 125000000335 thiazolyl group Chemical group 0.000 description 2
• 210000001685 thyroid gland Anatomy 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 238000006478 transmetalation reaction Methods 0.000 description 2
• AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
• CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
• IIFVWLUQBAIPMJ-UHFFFAOYSA-N (4-fluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C=C1 IIFVWLUQBAIPMJ-UHFFFAOYSA-N 0.000 description 1
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
• 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 description 1
• 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
• BPRSISHQMLQOMN-VMPITWQZSA-N (e)-3-[4-[2-(propylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]prop-2-enoic acid Chemical compound C=1N=C2SC(NCCC)=NN2C=1C1=CC=C(\C=C\C(O)=O)C=C1 BPRSISHQMLQOMN-VMPITWQZSA-N 0.000 description 1
• GETTZEONDQJALK-UHFFFAOYSA-N (trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 description 1
• RUAOUHQNNBBMGS-UHFFFAOYSA-N 1,1,1,2-tetrachloro-2,2-diiodoethane Chemical compound ClC(Cl)(Cl)C(Cl)(I)I RUAOUHQNNBBMGS-UHFFFAOYSA-N 0.000 description 1
• SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
• JNVXRQOSRUDXDY-UHFFFAOYSA-N 1,1-diiodoethane Chemical compound CC(I)I JNVXRQOSRUDXDY-UHFFFAOYSA-N 0.000 description 1
• 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
• 125000005943 1,2,3,6-tetrahydropyridyl group Chemical group 0.000 description 1
• 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
• 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
• 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
• 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
• 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
• 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
• NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
• 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
• QUKGLNCXGVWCJX-UHFFFAOYSA-N 1,3,4-thiadiazol-2-amine Chemical compound NC1=NN=CS1 QUKGLNCXGVWCJX-UHFFFAOYSA-N 0.000 description 1
• UXTIRLFDCHFIID-UHFFFAOYSA-N 1,3,4-thiadiazole-2-carbaldehyde Chemical compound O=CC1=NN=CS1 UXTIRLFDCHFIID-UHFFFAOYSA-N 0.000 description 1
• DERHNSJVDWFDKZ-UHFFFAOYSA-N 1,3,4-thiadiazole-2-carboxylic acid Chemical compound OC(=O)C1=NN=CS1 DERHNSJVDWFDKZ-UHFFFAOYSA-N 0.000 description 1
• 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
• IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
• JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
• FLOJNXXFMHCMMR-UHFFFAOYSA-N 1,3-dithiolanyl Chemical group [CH]1SCCS1 FLOJNXXFMHCMMR-UHFFFAOYSA-N 0.000 description 1
• 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
• HKDFRDIIELOLTJ-UHFFFAOYSA-N 1,4-dithianyl Chemical group [CH]1CSCCS1 HKDFRDIIELOLTJ-UHFFFAOYSA-N 0.000 description 1
• GPRYKVSEZCQIHD-UHFFFAOYSA-N 1-(4-aminophenyl)ethanone Chemical compound CC(=O)C1=CC=C(N)C=C1 GPRYKVSEZCQIHD-UHFFFAOYSA-N 0.000 description 1
• QBUHYMHIPRUAHM-UHFFFAOYSA-N 1-[3-[2-(1,3-benzodioxol-5-ylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC(C=2N3N=C(NCC=4C=C5OCOC5=CC=4)SC3=NC=2)=C1 QBUHYMHIPRUAHM-UHFFFAOYSA-N 0.000 description 1
• RVXYXVVILUCCAH-UHFFFAOYSA-N 1-[3-[2-(2-morpholin-4-ylethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC(C=2N3N=C(NCCN4CCOCC4)SC3=NC=2)=C1 RVXYXVVILUCCAH-UHFFFAOYSA-N 0.000 description 1
• WNNMDSHQQSETLW-UHFFFAOYSA-N 1-[3-[2-[(4-methoxyphenyl)methylamino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]ethanone Chemical compound C1=CC(OC)=CC=C1CNC(S1)=NN2C1=NC=C2C1=CC=CC(C(C)=O)=C1 WNNMDSHQQSETLW-UHFFFAOYSA-N 0.000 description 1
• GONRJIWQOBRGOR-UHFFFAOYSA-N 1-[4-[5-[(4-methoxyphenyl)methylamino]imidazo[2,1-b][1,3,4]thiadiazol-2-yl]phenyl]ethanone Chemical compound C1=CC(OC)=CC=C1CNC1=CN=C2N1N=C(C=1C=CC(=CC=1)C(C)=O)S2 GONRJIWQOBRGOR-UHFFFAOYSA-N 0.000 description 1
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
• ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
• WTHUZDCMEMDVAV-UHFFFAOYSA-N 2,5-diphenylimidazo[2,1-b][1,3,4]thiadiazole Chemical compound C=1N=C2SC(C=3C=CC=CC=3)=NN2C=1C1=CC=CC=C1 WTHUZDCMEMDVAV-UHFFFAOYSA-N 0.000 description 1
• AISKMOQBOFWLFR-UHFFFAOYSA-N 2-(2-methylpropylamino)-n-phenylimidazo[2,1-b][1,3,4]thiadiazole-5-sulfonamide Chemical compound C=1N=C2SC(NCC(C)C)=NN2C=1S(=O)(=O)NC1=CC=CC=C1 AISKMOQBOFWLFR-UHFFFAOYSA-N 0.000 description 1
• JRNUZJGZJZOYAB-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-n-(oxan-4-yl)imidazo[2,1-b][1,3,4]thiadiazol-5-amine Chemical compound C1=C(OC)C(OC)=CC=C1C(S1)=NN2C1=NC=C2NC1CCOCC1 JRNUZJGZJZOYAB-UHFFFAOYSA-N 0.000 description 1
• KOXRRHFBOQALQJ-UHFFFAOYSA-N 2-(dimethylamino)-7,7a-dihydroimidazo[2,1-b][1,3,4]thiadiazole-5-carbaldehyde Chemical compound S1C(N(C)C)=NN2C1NC=C2C=O KOXRRHFBOQALQJ-UHFFFAOYSA-N 0.000 description 1
• DMWXBQXISKJEDE-UHFFFAOYSA-N 2-(dimethylamino)imidazo[2,1-b][1,3,4]thiadiazole-5-carbaldehyde Chemical compound O=CC1=CN=C2SC(N(C)C)=NN21 DMWXBQXISKJEDE-UHFFFAOYSA-N 0.000 description 1
• UJYCDDNNOBCLSZ-UHFFFAOYSA-N 2-[(5-naphthalen-2-ylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)amino]ethanol Chemical compound C1=CC=CC2=CC(C=3N4N=C(SC4=NC=3)NCCO)=CC=C21 UJYCDDNNOBCLSZ-UHFFFAOYSA-N 0.000 description 1
• OJBVAXSBHIOYHY-UHFFFAOYSA-N 2-[5-(4-chlorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl]oxy-n-methylacetamide Chemical compound C=1N=C2SC(OCC(=O)NC)=NN2C=1C1=CC=C(Cl)C=C1 OJBVAXSBHIOYHY-UHFFFAOYSA-N 0.000 description 1
• AEGXSYHUTNVRRI-UHFFFAOYSA-N 2-[[5-(3,4-dimethoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl]amino]butan-1-ol Chemical compound C=1N=C2SC(NC(CO)CC)=NN2C=1C1=CC=C(OC)C(OC)=C1 AEGXSYHUTNVRRI-UHFFFAOYSA-N 0.000 description 1
• FEDUPUWLSQTTTC-UHFFFAOYSA-N 2-[[5-(3-chloro-4-fluorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl]amino]ethanol Chemical compound C=1N=C2SC(NCCO)=NN2C=1C1=CC=C(F)C(Cl)=C1 FEDUPUWLSQTTTC-UHFFFAOYSA-N 0.000 description 1
• TXHOKZKOFUTJRC-UHFFFAOYSA-N 2-[[5-(3-cyanophenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl]amino]acetic acid Chemical compound C=1N=C2SC(NCC(=O)O)=NN2C=1C1=CC=CC(C#N)=C1 TXHOKZKOFUTJRC-UHFFFAOYSA-N 0.000 description 1
• DKHNAOKCCZCUJO-UHFFFAOYSA-N 2-[[5-(3-fluorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl]amino]acetamide Chemical compound C=1N=C2SC(NCC(=O)N)=NN2C=1C1=CC=CC(F)=C1 DKHNAOKCCZCUJO-UHFFFAOYSA-N 0.000 description 1
• FHTJLIVTWPPTTI-UHFFFAOYSA-N 2-[[5-[3-(trifluoromethyl)phenyl]imidazo[2,1-b][1,3,4]thiadiazol-2-yl]amino]acetamide Chemical compound C=1N=C2SC(NCC(=O)N)=NN2C=1C1=CC=CC(C(F)(F)F)=C1 FHTJLIVTWPPTTI-UHFFFAOYSA-N 0.000 description 1
• VFOMZTWMSYRKRC-UHFFFAOYSA-N 2-bromo-7,7a-dihydroimidazo[2,1-b][1,3,4]thiadiazole-5-carbaldehyde;3-bromo-2,4-dihydroimidazo[4,5-d][1,3]thiazole Chemical compound N1=CNC2=C1SCN2Br.S1C(Br)=NN2C1NC=C2C=O VFOMZTWMSYRKRC-UHFFFAOYSA-N 0.000 description 1
• CWTLPSMNMHQWCV-UHFFFAOYSA-N 2-bromo-n-ethylimidazo[2,1-b][1,3,4]thiadiazole-5-sulfonamide Chemical compound S1C(Br)=NN2C(S(=O)(=O)NCC)=CN=C21 CWTLPSMNMHQWCV-UHFFFAOYSA-N 0.000 description 1
• QTNKRICUUZBICH-UHFFFAOYSA-N 2-bromo-n-phenylimidazo[2,1-b][1,3,4]thiadiazole-5-sulfonamide Chemical compound C=1N=C2SC(Br)=NN2C=1S(=O)(=O)NC1=CC=CC=C1 QTNKRICUUZBICH-UHFFFAOYSA-N 0.000 description 1
• 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• PXVCQYZKMBRTIW-UHFFFAOYSA-N 2-methoxy-4-[2-(2-methoxyethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenol Chemical compound C=1N=C2SC(NCCOC)=NN2C=1C1=CC=C(O)C(OC)=C1 PXVCQYZKMBRTIW-UHFFFAOYSA-N 0.000 description 1
• NOSVNPMFKHWHTE-UHFFFAOYSA-N 2-methoxy-n-[3-(trifluoromethyl)phenyl]imidazo[2,1-b][1,3,4]thiadiazol-5-amine Chemical compound C=1N=C2SC(OC)=NN2C=1NC1=CC=CC(C(F)(F)F)=C1 NOSVNPMFKHWHTE-UHFFFAOYSA-N 0.000 description 1
• 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
• 125000006179 2-methyl benzyl group Chemical group [H]C1=C([H])C(=C(C([H])=C1[H])C([H])([H])*)C([H])([H])[H] 0.000 description 1
• 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
• BXVSAYBZSGIURM-UHFFFAOYSA-N 2-phenoxy-4h-1,3,2$l^{5}-benzodioxaphosphinine 2-oxide Chemical compound O1CC2=CC=CC=C2OP1(=O)OC1=CC=CC=C1 BXVSAYBZSGIURM-UHFFFAOYSA-N 0.000 description 1
• OEGHJICHYPFZQI-UHFFFAOYSA-N 2-phenylimidazo[2,1-b][1,3,4]thiadiazole Chemical compound S1C2=NC=CN2N=C1C1=CC=CC=C1 OEGHJICHYPFZQI-UHFFFAOYSA-N 0.000 description 1
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• 125000006512 3,4-dichlorobenzyl group Chemical group [H]C1=C(Cl)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 description 1
• LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
• YKXHTEHVFNYIJO-UHFFFAOYSA-N 3-[2-(2-pyrazin-2-ylethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2N3N=C(NCCC=4N=CC=NC=4)SC3=NC=2)=C1 YKXHTEHVFNYIJO-UHFFFAOYSA-N 0.000 description 1
• WNOSANZIJVUADV-UHFFFAOYSA-N 3-[2-(cyclopropylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(C=2N3N=C(NCC4CC4)SC3=NC=2)=C1 WNOSANZIJVUADV-UHFFFAOYSA-N 0.000 description 1
• QXZWYIBQYBPJSG-UHFFFAOYSA-N 3-[2-(cyclopropylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-n-[2-(dimethylamino)ethyl]benzamide Chemical compound CN(C)CCNC(=O)C1=CC=CC(C=2N3N=C(NCC4CC4)SC3=NC=2)=C1 QXZWYIBQYBPJSG-UHFFFAOYSA-N 0.000 description 1
• RBUSWWHXOSBUDQ-UHFFFAOYSA-N 3-[[2-(3-chlorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]amino]benzoic acid Chemical compound OC(=O)C1=CC=CC(NC=2N3N=C(SC3=NC=2)C=2C=C(Cl)C=CC=2)=C1 RBUSWWHXOSBUDQ-UHFFFAOYSA-N 0.000 description 1
• XVKPPQLTLGXKRX-UHFFFAOYSA-N 3-acetamido-n-[2-[(3,4-dichlorophenyl)methylamino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]propanamide Chemical compound N=1N2C(NC(=O)CCNC(=O)C)=CN=C2SC=1NCC1=CC=C(Cl)C(Cl)=C1 XVKPPQLTLGXKRX-UHFFFAOYSA-N 0.000 description 1
• NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
• 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
• JYNJDULKNSARKX-UHFFFAOYSA-N 4-[(2-phenylsulfanylimidazo[2,1-b][1,3,4]thiadiazol-5-yl)amino]benzonitrile Chemical compound C1=CC(C#N)=CC=C1NC1=CN=C2N1N=C(SC=1C=CC=CC=1)S2 JYNJDULKNSARKX-UHFFFAOYSA-N 0.000 description 1
• OIFFZYUSDDUHAX-UHFFFAOYSA-N 4-[2-(2-methoxyethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzonitrile Chemical compound C=1N=C2SC(NCCOC)=NN2C=1C1=CC=C(C#N)C=C1 OIFFZYUSDDUHAX-UHFFFAOYSA-N 0.000 description 1
• WDTBCLHSFVDQFR-UHFFFAOYSA-N 4-[2-(2-phenylethynyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CN=C2N1N=C(C#CC=1C=CC=CC=1)S2 WDTBCLHSFVDQFR-UHFFFAOYSA-N 0.000 description 1
• IUZXAVUPOYMEGA-UHFFFAOYSA-N 4-[2-(3-hydroxypropylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzonitrile Chemical compound C=1N=C2SC(NCCCO)=NN2C=1C1=CC=C(C#N)C=C1 IUZXAVUPOYMEGA-UHFFFAOYSA-N 0.000 description 1
• RBKDSSSWSMXHNY-UHFFFAOYSA-N 4-[2-(4-fluorophenoxy)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C2N1N=C(OC=1C=CC(F)=CC=1)S2 RBKDSSSWSMXHNY-UHFFFAOYSA-N 0.000 description 1
• YYFVZYSDAYKPHY-UHFFFAOYSA-N 4-[2-(cyclopropylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-2,6-dimethylphenol Chemical compound CC1=C(O)C(C)=CC(C=2N3N=C(NCC4CC4)SC3=NC=2)=C1 YYFVZYSDAYKPHY-UHFFFAOYSA-N 0.000 description 1
• TXSMZUMNTPVXND-UHFFFAOYSA-N 4-[2-(cyclopropylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-n-(2-hydroxyethyl)benzamide Chemical compound C1=CC(C(=O)NCCO)=CC=C1C1=CN=C2N1N=C(NCC1CC1)S2 TXSMZUMNTPVXND-UHFFFAOYSA-N 0.000 description 1
• DCWSYLUITYNIGO-UHFFFAOYSA-N 4-[2-(cyclopropylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C2N1N=C(NCC1CC1)S2 DCWSYLUITYNIGO-UHFFFAOYSA-N 0.000 description 1
• LLKIZECKWXVXTN-UHFFFAOYSA-N 4-[2-(furan-2-ylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-2,6-dimethylphenol Chemical compound CC1=C(O)C(C)=CC(C=2N3N=C(NCC=4OC=CC=4)SC3=NC=2)=C1 LLKIZECKWXVXTN-UHFFFAOYSA-N 0.000 description 1
• CYSSZRBXBMTMJN-UHFFFAOYSA-N 4-[2-(furan-2-ylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C2N1N=C(NCC=1OC=CC=1)S2 CYSSZRBXBMTMJN-UHFFFAOYSA-N 0.000 description 1
• RZVALJNOJASENH-UHFFFAOYSA-N 4-[2-(oxan-4-ylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CN=C2N1N=C(NC1CCOCC1)S2 RZVALJNOJASENH-UHFFFAOYSA-N 0.000 description 1
• OUQJCXXWLCNAMH-UHFFFAOYSA-N 4-[2-[(3,4-dichlorophenyl)methylamino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CN=C2N1N=C(NCC=1C=C(Cl)C(Cl)=CC=1)S2 OUQJCXXWLCNAMH-UHFFFAOYSA-N 0.000 description 1
• UYBUQAUXGAHMEO-UHFFFAOYSA-N 4-[2-[(3-chlorobenzoyl)amino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CN=C2N1N=C(NC(=O)C=1C=C(Cl)C=CC=1)S2 UYBUQAUXGAHMEO-UHFFFAOYSA-N 0.000 description 1
• NJYLAAKOAVHNDS-UHFFFAOYSA-N 4-[2-[(3-chlorophenyl)methylamino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CN=C2N1N=C(NCC=1C=C(Cl)C=CC=1)S2 NJYLAAKOAVHNDS-UHFFFAOYSA-N 0.000 description 1
• GPTLOEFMTXIAFG-UHFFFAOYSA-N 4-[2-[(4-chloro-3-fluorophenyl)methoxy]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]morpholine Chemical compound C1=C(Cl)C(F)=CC(COC=2SC3=NC=C(N3N=2)N2CCOCC2)=C1 GPTLOEFMTXIAFG-UHFFFAOYSA-N 0.000 description 1
• QNNMNDPDEFCPEL-UHFFFAOYSA-N 4-[2-[(4-methoxyphenyl)methylamino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzoic acid Chemical compound C1=CC(OC)=CC=C1CNC(S1)=NN2C1=NC=C2C1=CC=C(C(O)=O)C=C1 QNNMNDPDEFCPEL-UHFFFAOYSA-N 0.000 description 1
• QSJRRKDQFXJZPP-UHFFFAOYSA-N 4-[2-[[2-(methylamino)-2-oxoethyl]amino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzoic acid Chemical compound C=1N=C2SC(NCC(=O)NC)=NN2C=1C1=CC=C(C(O)=O)C=C1 QSJRRKDQFXJZPP-UHFFFAOYSA-N 0.000 description 1
• OXLQGNMLAWCZDG-UHFFFAOYSA-N 4-[[(5-naphthalen-2-ylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)amino]methyl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1CNC(S1)=NN2C1=NC=C2C1=CC=C(C=CC=C2)C2=C1 OXLQGNMLAWCZDG-UHFFFAOYSA-N 0.000 description 1
• DOKIHNBETLEOKV-UHFFFAOYSA-N 4-[[5-[3-(trifluoromethyl)phenyl]imidazo[2,1-b][1,3,4]thiadiazol-2-yl]amino]cyclohexan-1-ol Chemical compound C1CC(O)CCC1NC(S1)=NN2C1=NC=C2C1=CC=CC(C(F)(F)F)=C1 DOKIHNBETLEOKV-UHFFFAOYSA-N 0.000 description 1
• YTSADIUOTOUBFV-UHFFFAOYSA-N 4-[[[5-(6-methoxypyridin-3-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl]amino]methyl]benzenesulfonamide Chemical compound C1=NC(OC)=CC=C1C1=CN=C2N1N=C(NCC=1C=CC(=CC=1)S(N)(=O)=O)S2 YTSADIUOTOUBFV-UHFFFAOYSA-N 0.000 description 1
• 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
• KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
• RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 1
• 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000004606 5,6,7,8-tetrahydroisoquinolinyl group Chemical group C1(=NC=CC=2CCCCC12)* 0.000 description 1
• 125000004608 5,6,7,8-tetrahydroquinolinyl group Chemical group N1=C(C=CC=2CCCCC12)* 0.000 description 1
• RGIWIBHXIJDYMR-UHFFFAOYSA-N 5-(1h-indol-6-yl)-2-phenylimidazo[2,1-b][1,3,4]thiadiazole Chemical compound C1=C2NC=CC2=CC=C1C(N1N=2)=CN=C1SC=2C1=CC=CC=C1 RGIWIBHXIJDYMR-UHFFFAOYSA-N 0.000 description 1
• OKFNARGTEHFFSO-UHFFFAOYSA-N 5-(2-chlorophenyl)-n-(cyclopropylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound ClC1=CC=CC=C1C1=CN=C2N1N=C(NCC1CC1)S2 OKFNARGTEHFFSO-UHFFFAOYSA-N 0.000 description 1
• FSXZHSBSMPBIHD-UHFFFAOYSA-N 5-(2-chlorophenyl)-n-(oxan-4-ylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound ClC1=CC=CC=C1C1=CN=C2N1N=C(NCC1CCOCC1)S2 FSXZHSBSMPBIHD-UHFFFAOYSA-N 0.000 description 1
• DWFWVCHMFZGQFM-UHFFFAOYSA-N 5-(3,4-dimethoxyphenyl)-n-(2-methylpropyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1C1=CN=C2N1N=C(NCC(C)C)S2 DWFWVCHMFZGQFM-UHFFFAOYSA-N 0.000 description 1
• CCEKYNCIKDHLBO-UHFFFAOYSA-N 5-(3,4-dimethoxyphenyl)-n-(oxan-4-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1C1=CN=C2N1N=C(NC1CCOCC1)S2 CCEKYNCIKDHLBO-UHFFFAOYSA-N 0.000 description 1
• UHKTZSPAXISGQL-UHFFFAOYSA-N 5-(3,5-difluorophenyl)-n-(2-morpholin-4-ylethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound FC1=CC(F)=CC(C=2N3N=C(NCCN4CCOCC4)SC3=NC=2)=C1 UHKTZSPAXISGQL-UHFFFAOYSA-N 0.000 description 1
• NWFJOWJTGMOMJG-UHFFFAOYSA-N 5-(3-chloro-4-fluorophenyl)-n-(1h-pyrrol-2-ylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=C(Cl)C(F)=CC=C1C1=CN=C2N1N=C(NCC=1NC=CC=1)S2 NWFJOWJTGMOMJG-UHFFFAOYSA-N 0.000 description 1
• CDBZUHPKCWJXHR-UHFFFAOYSA-N 5-(3-chlorophenyl)-n-(cyclopropylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound ClC1=CC=CC(C=2N3N=C(NCC4CC4)SC3=NC=2)=C1 CDBZUHPKCWJXHR-UHFFFAOYSA-N 0.000 description 1
• URUYOPINPBEWQF-UHFFFAOYSA-N 5-(3-chlorophenyl)-n-[(4-fluorophenyl)methyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(F)=CC=C1CNC(S1)=NN2C1=NC=C2C1=CC=CC(Cl)=C1 URUYOPINPBEWQF-UHFFFAOYSA-N 0.000 description 1
• YRZVPHJQUGHMOJ-UHFFFAOYSA-N 5-(3-fluorophenyl)-n-(2-methoxyethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1N=C2SC(NCCOC)=NN2C=1C1=CC=CC(F)=C1 YRZVPHJQUGHMOJ-UHFFFAOYSA-N 0.000 description 1
• DZQUEOZCGAAUTO-UHFFFAOYSA-N 5-(3-fluorophenyl)-n-(oxan-4-ylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound FC1=CC=CC(C=2N3N=C(NCC4CCOCC4)SC3=NC=2)=C1 DZQUEOZCGAAUTO-UHFFFAOYSA-N 0.000 description 1
• KXEKDQIECACWFS-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-[(4-fluorophenyl)methyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(F)=CC=C1CNC(S1)=NN2C1=NC=C2C1=CC=C(Cl)C=C1 KXEKDQIECACWFS-UHFFFAOYSA-N 0.000 description 1
• JLMBQTZSDTWJNO-UHFFFAOYSA-N 5-(5-methoxypyridin-3-yl)-n-(2-methylpropyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound COC1=CN=CC(C=2N3N=C(NCC(C)C)SC3=NC=2)=C1 JLMBQTZSDTWJNO-UHFFFAOYSA-N 0.000 description 1
• HIMBVBHJQNZPGV-UHFFFAOYSA-N 5-(5-methoxypyridin-3-yl)-n-(oxan-4-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound COC1=CN=CC(C=2N3N=C(NC4CCOCC4)SC3=NC=2)=C1 HIMBVBHJQNZPGV-UHFFFAOYSA-N 0.000 description 1
• OWOABVSPCSGYJF-UHFFFAOYSA-N 5-(5-methoxypyridin-3-yl)-n-(oxan-4-ylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound COC1=CN=CC(C=2N3N=C(NCC4CCOCC4)SC3=NC=2)=C1 OWOABVSPCSGYJF-UHFFFAOYSA-N 0.000 description 1
• IKAJIIIXTORULG-UHFFFAOYSA-N 5-(5-methoxypyridin-3-yl)-n-(thiophen-2-ylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound COC1=CN=CC(C=2N3N=C(NCC=4SC=CC=4)SC3=NC=2)=C1 IKAJIIIXTORULG-UHFFFAOYSA-N 0.000 description 1
• VQNVUAUJUIRXSL-UHFFFAOYSA-N 5-(6-methoxypyridin-3-yl)-n-(oxan-4-ylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=NC(OC)=CC=C1C1=CN=C2N1N=C(NCC1CCOCC1)S2 VQNVUAUJUIRXSL-UHFFFAOYSA-N 0.000 description 1
• ZGRBXIQRUFYTAI-UHFFFAOYSA-N 5-(6-methoxypyridin-3-yl)-n-(thiophen-2-ylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=NC(OC)=CC=C1C1=CN=C2N1N=C(NCC=1SC=CC=1)S2 ZGRBXIQRUFYTAI-UHFFFAOYSA-N 0.000 description 1
• CARXPXGXWCKBJL-UHFFFAOYSA-N 5-[(3-chloro-4-fluoroanilino)methyl]-n-(2-methylpropyl)-7,7a-dihydroimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound S1C(NCC(C)C)=NN2C1NC=C2CNC1=CC=C(F)C(Cl)=C1 CARXPXGXWCKBJL-UHFFFAOYSA-N 0.000 description 1
• CJFCWJPEXFBTQS-UHFFFAOYSA-N 5-iodo-n-(2-methoxyethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound IC1=CN=C2SC(NCCOC)=NN21 CJFCWJPEXFBTQS-UHFFFAOYSA-N 0.000 description 1
• BJHAGDWMARLZGE-UHFFFAOYSA-N 5-naphthalen-2-yl-n-(thiophen-2-ylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound N=1N2C(C=3C=C4C=CC=CC4=CC=3)=CN=C2SC=1NCC1=CC=CS1 BJHAGDWMARLZGE-UHFFFAOYSA-N 0.000 description 1
• QJSZXZWMKYASRV-UHFFFAOYSA-N 5-phenyl-3h-thiadiazol-2-amine Chemical compound S1N(N)NC=C1C1=CC=CC=C1 QJSZXZWMKYASRV-UHFFFAOYSA-N 0.000 description 1
• XDZAUUQMNKFTAJ-UHFFFAOYSA-N 6-chloro-n-(cyclopropylmethyl)-5-[3-(dimethylamino)phenyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound CN(C)C1=CC=CC(C=2N3N=C(NCC4CC4)SC3=NC=2Cl)=C1 XDZAUUQMNKFTAJ-UHFFFAOYSA-N 0.000 description 1
• NGTZLYHDVCVIEY-UHFFFAOYSA-N 6-chloro-n-[(4-fluorophenyl)methyl]-5-iodoimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(F)=CC=C1CNC(S1)=NN2C1=NC(Cl)=C2I NGTZLYHDVCVIEY-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
• 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
• DCLNFTWENAUIPQ-UHFFFAOYSA-N BrC1=NN2C(S1)=NC=C2S(=O)(=O)O.BrC2=NN1C(S2)=NC=C1S(=O)(=O)Cl Chemical compound BrC1=NN2C(S1)=NC=C2S(=O)(=O)O.BrC2=NN1C(S2)=NC=C1S(=O)(=O)Cl DCLNFTWENAUIPQ-UHFFFAOYSA-N 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• OIFUWKCICRUDOA-UHFFFAOYSA-P C=1C=CC=CC=1P(C=1C=CC=CC=1)(C=1C=CC=CC=1)[Cu](P(C=1C=CC=CC=1)(C=1C=CC=CC=1)C=1C=CC=CC=1)(Br)P(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(C=1C=CC=CC=1)[Cu](P(C=1C=CC=CC=1)(C=1C=CC=CC=1)C=1C=CC=CC=1)(Br)P(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 OIFUWKCICRUDOA-UHFFFAOYSA-P 0.000 description 1
• JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 101710178035 Chorismate synthase 2 Proteins 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 1
• 101710152694 Cysteine synthase 2 Proteins 0.000 description 1
• OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
• 101100457919 Drosophila melanogaster stg gene Proteins 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
• 102000003951 Erythropoietin Human genes 0.000 description 1
• 108090000394 Erythropoietin Proteins 0.000 description 1
• 241000400611 Eucalyptus deanei Species 0.000 description 1
• 201000008808 Fibrosarcoma Diseases 0.000 description 1
• 208000034951 Genetic Translocation Diseases 0.000 description 1
• 208000032612 Glial tumor Diseases 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• 108010044091 Globulins Proteins 0.000 description 1
• 102000006395 Globulins Human genes 0.000 description 1
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 101000944380 Homo sapiens Cyclin-dependent kinase inhibitor 1 Proteins 0.000 description 1
• 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
• 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 description 1
• 241000764238 Isis Species 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 241000714177 Murine leukemia virus Species 0.000 description 1
• 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
• 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1
• 102000043276 Oncogene Human genes 0.000 description 1
• 102000038030 PI3Ks Human genes 0.000 description 1
• 108091007960 PI3Ks Proteins 0.000 description 1
• 229910002666 PdCl2 Inorganic materials 0.000 description 1
• YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 102000003946 Prolactin Human genes 0.000 description 1
• 108010057464 Prolactin Proteins 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 108010087776 Proto-Oncogene Proteins c-myb Proteins 0.000 description 1
• 102000009096 Proto-Oncogene Proteins c-myb Human genes 0.000 description 1
• 102000007078 STAT Transcription Factors Human genes 0.000 description 1
• 108010072819 STAT Transcription Factors Proteins 0.000 description 1
• 201000010208 Seminoma Diseases 0.000 description 1
• 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
• 102100036077 Serine/threonine-protein kinase pim-1 Human genes 0.000 description 1
• XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
• 206010041067 Small cell lung cancer Diseases 0.000 description 1
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
• 206010052779 Transplant rejections Diseases 0.000 description 1
• 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 150000001263 acyl chlorides Chemical class 0.000 description 1
• 125000005907 alkyl ester group Chemical group 0.000 description 1
• 125000004414 alkyl thio group Chemical group 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 125000000539 amino acid group Chemical group 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 230000006909 anti-apoptosis Effects 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000012300 argon atmosphere Substances 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 238000010533 azeotropic distillation Methods 0.000 description 1
• 239000003899 bactericide agent Substances 0.000 description 1
• UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
• 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
• 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
• 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
• 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
• MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical group C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000002051 biphasic effect Effects 0.000 description 1
• PFYXSUNOLOJMDX-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)ON1C(=O)CCC1=O PFYXSUNOLOJMDX-UHFFFAOYSA-N 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• 244000309464 bull Species 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 230000036952 cancer formation Effects 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
• 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
• XEVRDFDBXJMZFG-UHFFFAOYSA-N carbonyl dihydrazine Chemical group NNC(=O)NN XEVRDFDBXJMZFG-UHFFFAOYSA-N 0.000 description 1
• 125000005392 carboxamide group Chemical group NC(=O)* 0.000 description 1
• 150000003857 carboxamides Chemical class 0.000 description 1
• 125000002843 carboxylic acid group Chemical group 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
• 101150069072 cdc25 gene Proteins 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 210000003679 cervix uteri Anatomy 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 239000012069 chiral reagent Substances 0.000 description 1
• 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 150000003983 crown ethers Chemical class 0.000 description 1
• 239000013058 crude material Substances 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 125000000392 cycloalkenyl group Chemical group 0.000 description 1
• UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
• KFGVRWGDTLZAAO-UHFFFAOYSA-N cyclopenta-1,3-diene dicyclohexyl(cyclopenta-1,3-dien-1-yl)phosphane iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.C1CCC(CC1)P(C1CCCCC1)c1ccc[cH-]1 KFGVRWGDTLZAAO-UHFFFAOYSA-N 0.000 description 1
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 150000004985 diamines Chemical class 0.000 description 1
• WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
• BUMGIEFFCMBQDG-UHFFFAOYSA-N dichlorosilicon Chemical compound Cl[Si]Cl BUMGIEFFCMBQDG-UHFFFAOYSA-N 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
• 125000000532 dioxanyl group Chemical group 0.000 description 1
• 125000005879 dioxolanyl group Chemical group 0.000 description 1
• LMAJREOZDVKQCZ-UHFFFAOYSA-N ditert-butyl-[2-(2-ditert-butylphosphanylphenyl)phenyl]phosphane Chemical group CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1C1=CC=CC=C1P(C(C)(C)C)C(C)(C)C LMAJREOZDVKQCZ-UHFFFAOYSA-N 0.000 description 1
• 125000005883 dithianyl group Chemical group 0.000 description 1
• 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 230000008482 dysregulation Effects 0.000 description 1
• 239000012039 electrophile Substances 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 238000006345 epimerization reaction Methods 0.000 description 1
• 229940105423 erythropoietin Drugs 0.000 description 1
• 210000003238 esophagus Anatomy 0.000 description 1
• 125000004494 ethyl ester group Chemical group 0.000 description 1
• WUOIAOOSKMHJOV-UHFFFAOYSA-N ethyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(CC)C1=CC=CC=C1 WUOIAOOSKMHJOV-UHFFFAOYSA-N 0.000 description 1
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
• 239000000706 filtrate Substances 0.000 description 1
• 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
• 230000003325 follicular Effects 0.000 description 1
• 238000001640 fractional crystallisation Methods 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 210000000232 gallbladder Anatomy 0.000 description 1
• 108010074605 gamma-Globulins Proteins 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 229960001867 guaiacol Drugs 0.000 description 1
• 230000003394 haemopoietic effect Effects 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 210000000777 hematopoietic system Anatomy 0.000 description 1
• 239000004009 herbicide Substances 0.000 description 1
• 125000004474 heteroalkylene group Chemical group 0.000 description 1
• 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
• 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
• 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
• 125000002636 imidazolinyl group Chemical group 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 238000012739 integrated shape imaging system Methods 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 229940043355 kinase inhibitor Drugs 0.000 description 1
• 239000010410 layer Substances 0.000 description 1
• 231100001231 less toxic Toxicity 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
• DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
• UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 229910001629 magnesium chloride Inorganic materials 0.000 description 1
• 230000007257 malfunction Effects 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 230000007721 medicinal effect Effects 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 230000003340 mental effect Effects 0.000 description 1
• 239000002808 molecular sieve Substances 0.000 description 1
• 229960005181 morphine Drugs 0.000 description 1
• 108700024542 myc Genes Proteins 0.000 description 1
• XTLUNENWXYJDSO-UHFFFAOYSA-N n-(1,3-benzodioxol-5-ylmethyl)-5-(4-chlorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(Cl)=CC=C1C1=CN=C2N1N=C(NCC=1C=C3OCOC3=CC=1)S2 XTLUNENWXYJDSO-UHFFFAOYSA-N 0.000 description 1
• ZFSPSYARQVWKDR-UHFFFAOYSA-N n-(2-hydroxyethyl)-4-[2-(oxan-4-ylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzamide Chemical compound C1=CC(C(=O)NCCO)=CC=C1C1=CN=C2N1N=C(NCC1CCOCC1)S2 ZFSPSYARQVWKDR-UHFFFAOYSA-N 0.000 description 1
• MOJYWKGKUILWBJ-UHFFFAOYSA-N n-(2-methoxyethyl)-5-(6-methoxypyridin-3-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1N=C2SC(NCCOC)=NN2C=1C1=CC=C(OC)N=C1 MOJYWKGKUILWBJ-UHFFFAOYSA-N 0.000 description 1
• CCDJMYZAXVOYEP-UHFFFAOYSA-N n-(2-methoxyethyl)-5-[3-(trifluoromethoxy)phenyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1N=C2SC(NCCOC)=NN2C=1C1=CC=CC(OC(F)(F)F)=C1 CCDJMYZAXVOYEP-UHFFFAOYSA-N 0.000 description 1
• KYHMXRQTDLZCKP-UHFFFAOYSA-N n-(2-methoxyethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CN=C2SC(NCCOC)=NN21 KYHMXRQTDLZCKP-UHFFFAOYSA-N 0.000 description 1
• PBJXLEWFHAJFRQ-UHFFFAOYSA-N n-(3-fluorophenyl)-2-phenoxyimidazo[2,1-b][1,3,4]thiadiazol-5-amine Chemical compound FC1=CC=CC(NC=2N3N=C(OC=4C=CC=CC=4)SC3=NC=2)=C1 PBJXLEWFHAJFRQ-UHFFFAOYSA-N 0.000 description 1
• VHYGTQCSYAQOLI-UHFFFAOYSA-N n-(3-imidazol-1-ylpropyl)-5-[4-(trifluoromethoxy)phenyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN=C2N1N=C(NCCCN1C=NC=C1)S2 VHYGTQCSYAQOLI-UHFFFAOYSA-N 0.000 description 1
• CGWJLHITDDYAMZ-UHFFFAOYSA-N n-(cyclopropylmethyl)-5-(3,4-dimethoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1C1=CN=C2N1N=C(NCC1CC1)S2 CGWJLHITDDYAMZ-UHFFFAOYSA-N 0.000 description 1
• QZRKHFUOAFSPNE-UHFFFAOYSA-N n-(cyclopropylmethyl)-5-(5-methoxypyridin-3-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound COC1=CN=CC(C=2N3N=C(NCC4CC4)SC3=NC=2)=C1 QZRKHFUOAFSPNE-UHFFFAOYSA-N 0.000 description 1
• PBYJYCODVPYEFO-UHFFFAOYSA-N n-(cyclopropylmethyl)-5-(6-methoxypyridin-3-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=NC(OC)=CC=C1C1=CN=C2N1N=C(NCC1CC1)S2 PBYJYCODVPYEFO-UHFFFAOYSA-N 0.000 description 1
• FOIROZXHNLZCFE-UHFFFAOYSA-N n-(cyclopropylmethyl)-5-[3-(trifluoromethoxy)phenyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound FC(F)(F)OC1=CC=CC(C=2N3N=C(NCC4CC4)SC3=NC=2)=C1 FOIROZXHNLZCFE-UHFFFAOYSA-N 0.000 description 1
• AYHVFLVXXWZGCF-UHFFFAOYSA-N n-(cyclopropylmethyl)-5-[4-(trifluoromethyl)phenyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CN=C2N1N=C(NCC1CC1)S2 AYHVFLVXXWZGCF-UHFFFAOYSA-N 0.000 description 1
• VSNRREGQNSELCB-UHFFFAOYSA-N n-(cyclopropylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound N=1N2C=CN=C2SC=1NCC1CC1 VSNRREGQNSELCB-UHFFFAOYSA-N 0.000 description 1
• LWQHPDYYKSJORY-UHFFFAOYSA-N n-(oxan-4-ylmethyl)-5-phenylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1COCCC1CNC(SC1=NC=2)=NN1C=2C1=CC=CC=C1 LWQHPDYYKSJORY-UHFFFAOYSA-N 0.000 description 1
• MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
• JJCKCEFEVHIGGC-UHFFFAOYSA-N n-[(2-bromoimidazo[2,1-b][1,3,4]thiadiazol-5-yl)methyl]-3,4-dimethoxyaniline Chemical compound C1=C(OC)C(OC)=CC=C1NCC1=CN=C2N1N=C(Br)S2 JJCKCEFEVHIGGC-UHFFFAOYSA-N 0.000 description 1
• XZEXRSDLYCSRJD-UHFFFAOYSA-N n-[(3,4-dichlorophenyl)methyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=C(Cl)C(Cl)=CC=C1CNC(S1)=NN2C1=NC=C2 XZEXRSDLYCSRJD-UHFFFAOYSA-N 0.000 description 1
• YINAHDDRPAMQBB-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-5-(5-methoxypyridin-3-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound COC1=CN=CC(C=2N3N=C(NCC=4C=CC(F)=CC=4)SC3=NC=2)=C1 YINAHDDRPAMQBB-UHFFFAOYSA-N 0.000 description 1
• HZHHADDTOWKLHE-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-5-(6-methoxypyridin-3-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=NC(OC)=CC=C1C1=CN=C2N1N=C(NCC=1C=CC(F)=CC=1)S2 HZHHADDTOWKLHE-UHFFFAOYSA-N 0.000 description 1
• BYMPEVBUHPBMPL-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-5-morpholin-4-ylsulfonylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(F)=CC=C1CNC(S1)=NN2C1=NC=C2S(=O)(=O)N1CCOCC1 BYMPEVBUHPBMPL-UHFFFAOYSA-N 0.000 description 1
• NEHGQYYUYZAZGD-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-5-naphthalen-2-ylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(F)=CC=C1CNC(S1)=NN2C1=NC=C2C1=CC=C(C=CC=C2)C2=C1 NEHGQYYUYZAZGD-UHFFFAOYSA-N 0.000 description 1
• WKTUYYCWVFVSRA-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(F)=CC=C1CNC(S1)=NN2C1=NC=C2 WKTUYYCWVFVSRA-UHFFFAOYSA-N 0.000 description 1
• JBKUQDZWQHTQLK-UHFFFAOYSA-N n-[3-[2-(2-methoxyethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]acetamide Chemical compound C=1N=C2SC(NCCOC)=NN2C=1C1=CC=CC(NC(C)=O)=C1 JBKUQDZWQHTQLK-UHFFFAOYSA-N 0.000 description 1
• ONABRYSWQOPWAH-UHFFFAOYSA-N n-[3-[2-[[4-(dimethylamino)phenyl]methylamino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]acetamide Chemical compound C1=CC(N(C)C)=CC=C1CNC(S1)=NN2C1=NC=C2C1=CC=CC(NC(C)=O)=C1 ONABRYSWQOPWAH-UHFFFAOYSA-N 0.000 description 1
• JTGCSPVFAXPELK-UHFFFAOYSA-N n-[5-(3-acetylphenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl]propanamide Chemical compound C=1N=C2SC(NC(=O)CC)=NN2C=1C1=CC=CC(C(C)=O)=C1 JTGCSPVFAXPELK-UHFFFAOYSA-N 0.000 description 1
• QMWXEPORZMVMOB-UHFFFAOYSA-N n-cyclohexyl-5-(5-methoxypyridin-3-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound COC1=CN=CC(C=2N3N=C(NC4CCCCC4)SC3=NC=2)=C1 QMWXEPORZMVMOB-UHFFFAOYSA-N 0.000 description 1
• RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
• 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
• 230000009707 neogenesis Effects 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 208000004296 neuralgia Diseases 0.000 description 1
• 208000007538 neurilemmoma Diseases 0.000 description 1
• 208000021722 neuropathic pain Diseases 0.000 description 1
• QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 231100000590 oncogenic Toxicity 0.000 description 1
• 230000002246 oncogenic effect Effects 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 125000003566 oxetanyl group Chemical group 0.000 description 1
• 239000007800 oxidant agent Substances 0.000 description 1
• 125000000466 oxiranyl group Chemical group 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• 150000002978 peroxides Chemical class 0.000 description 1
• 239000003444 phase transfer catalyst Substances 0.000 description 1
• 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
• 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
• RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
• 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 229910000027 potassium carbonate Inorganic materials 0.000 description 1
• LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
• 230000003334 potential effect Effects 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 238000002953 preparative HPLC Methods 0.000 description 1
• 150000003141 primary amines Chemical class 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 229940097325 prolactin Drugs 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
• 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
• 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
• 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
• 125000001422 pyrrolinyl group Chemical group 0.000 description 1
• 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
• 108020003175 receptors Proteins 0.000 description 1
• 102000005962 receptors Human genes 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 230000022983 regulation of cell cycle Effects 0.000 description 1
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
• 229910052702 rhenium Inorganic materials 0.000 description 1
• 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
• 238000011894 semi-preparative HPLC Methods 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
• 239000012312 sodium hydride Substances 0.000 description 1
• AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
• 235000019345 sodium thiosulphate Nutrition 0.000 description 1
• 239000008279 sol Substances 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 125000000565 sulfonamide group Chemical group 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• 125000000542 sulfonic acid group Chemical group 0.000 description 1
• 150000003461 sulfonyl halides Chemical class 0.000 description 1
• HIFJUMGIHIZEPX-UHFFFAOYSA-N sulfuric acid;sulfur trioxide Chemical compound O=S(=O)=O.OS(O)(=O)=O HIFJUMGIHIZEPX-UHFFFAOYSA-N 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 238000003419 tautomerization reaction Methods 0.000 description 1
• 208000001608 teratocarcinoma Diseases 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
• 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• AQJBGXWYCYYFQT-UHFFFAOYSA-N thiadiazole-5-sulfonic acid Chemical compound S1N=NC=C1S(=O)(=O)O AQJBGXWYCYYFQT-UHFFFAOYSA-N 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• 210000001541 thymus gland Anatomy 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• BPLUKJNHPBNVQL-UHFFFAOYSA-N triphenylarsine Chemical compound C1=CC=CC=C1[As](C=1C=CC=CC=1)C1=CC=CC=C1 BPLUKJNHPBNVQL-UHFFFAOYSA-N 0.000 description 1
• BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 1
• 125000005455 trithianyl group Chemical group 0.000 description 1
• 210000003932 urinary bladder Anatomy 0.000 description 1
• 238000003828 vacuum filtration Methods 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000011592 zinc chloride Substances 0.000 description 1
• 235000005074 zinc chloride Nutrition 0.000 description 1
• JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1